XML 23 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Cash flows from operating activities:    
Net loss $ (47,506,869) $ (11,150,792)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 1,292,696 733,722
Amortization of intangible assets 968,986 658,049
Change in value of common stock warrants 517,334 (467,877)
Stock-based compensation 7,384,318 4,900,898
Amortization of premiums on investments 200,000 242,384
Gain on short-term investments (44,928) 0
Deferred rent (125,408) 317,922
Gain on investment in affiliated entity (5,817,309) (5,849,782)
Gain on sale of intangible assets (1,000,000) (1,000,000)
Income tax benefit from other unrealized gains on securities 0 (1,789,246)
Changes in operating assets and liabilities:    
Accounts receivable (10,122,049) (8,161,066)
Prepaid expenses and other current assets (473,995) (550,917)
Prepaid expenses and other current assets from affiliated entity (1,086,561) 748,049
Other assets (811,233) (123,002)
Accounts payable and accrued expenses 2,949,097 2,390,927
Accrued clinical trial expenses 4,615,783 935,012
Accounts payable and accrued expenses due to affiliated entity 328,373 2,784,612
Deferred revenue 1,642,479 9,625,906
Deferred revenue from affiliated entity (562,827) 90,239
Net cash used in operating activities (47,652,113) (5,664,962)
Cash flows from investing activities:    
Purchases of investments (42,495,236) (37,391,913)
Maturities of investments 51,721,024 4,745,000
Purchases of capital assets (2,672,235) (1,955,621)
Proceeds from sale of intangible assets 1,000,000 1,000,000
Purchase of intangible assets and other assets (1,200,000) 0
Net cash provided by (used in) investing activities 6,353,553 (33,602,534)
Cash flows from financing activities:    
Proceeds from issuance of common stock, net of issuance costs 5,458,284 81,902,363
Proceeds from stock option and warrant exercises, net of tax payments 1,607,904 2,439,506
Other financing activities (149,559) (149,559)
Net cash provided by financing activities 6,916,629 84,192,310
(Decrease) Increase in cash and cash equivalents (34,381,931) 44,924,814
Cash and cash equivalents, beginning of period 57,632,693 40,543,982
Cash and cash equivalents, end of period 23,250,762 85,468,796
Supplemental disclosure of non-cash activities    
Common stock issued for purchase of Bioject 4,300,000 0
Change in amounts accrued for purchases of property and equipment 169,980 475,123
Lease incentive recorded as fixed assets and deferred rent $ 134,500 $ 186,573